Abstracts tagged "lupus nephritis and prognostic factors"

Abstract Number: 701 • 2019 ACR/ARP Annual Meeting
Association of Cumulative Urinary Podocyte Number and Urinary Podocalyxin with Long-term Renal Prognosis in Lupus Nephritis
Hiroshi Kajiyama¹, Hidekazu Ikeuchi ², Junya Suwa ², Daisuke Ikuma ³, Hiroyuki Kurosawa ⁴, Yoshiaki Hirayama ⁴, Masanori Hara ⁵, Yoshihisa Nojima ⁶, Keiju Hiromura ² and Toshihide Mimura ⁷, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Nerima, Tokyo, Japan, ²Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gumma, Japan, ³Department of Rheumatology, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan, ⁴Department of reagent research and development, Denka Seiken Co. Ltd., Gosen, Niigata, Japan, ⁵Iwamuro health promotion center, Iwamuro-onsen, Niigata, Japan, ⁶Gunma Rheumatology Clinic, Takasaki, Gumma, Japan, ⁷Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Podocytes, glomerular visceral epithelial cells, function as molecular sieve not to filter high molecular weight proteins such as albumin and globulins. Various immunological insults…
Abstract Number: 2823 • 2016 ACR/ARHP Annual Meeting
Urinary Angiostatin, CXCL4 and VCAM-1 As Biomarkers for Lupus Nephritis
Chi Chiu Mok¹, Samar Soliman², Ling Yin Ho³ and Chandra Mohan², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Biomedical Engineering, University of Houston, Houston, TX, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: Proteomic screening is an efficient approach for identifying protein biomarkers in various inflammatory diseases. Our preliminary proteomic analysis revealed elevated levels of urinary angiostatin,…
Abstract Number: 1650 • 2014 ACR/ARHP Annual Meeting
Prevalence and Prognostic Implications of IgG4 in Membranous Lupus Nephritis
David Herrera Van Oostdam¹, Marco Ulises Martinez-Martinez¹, Cuauhtémoc Oros-Ovalle², David Martínez-Galla², Gerardo Tonatiu Jaimes-Piñón¹, Natalia Alemán-Sánchez² and Carlos Abud-Mendoza¹, ¹Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ²Patología, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
Background/Purpose: Patients with membranous lupus nephritis (MLN) have increased risk of thrombosis and different prognosis than other classes of lupus nephritis (LN). Previous studies demonstrated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].